Soleno Therapeutics, Inc. - Rasio total nilai perusahaan marang pendapatan SLNO

Anticipation of drug approvals caused a cash deficit, which triggered a spike on the Soleno Therapeutics (SLNO) EV/Sales chart. The 8987.61 metric confirms the current level of market valuation. Business stability is based on outsourcing production through contract manufacturing plants, while intellectual potential is provided by high-paid endocrinologists creating unique medications for rare metabolic pathologies.
SLNO (soleno.life): rincian analitis lan laporan miturut indikator

This indicator determines the enterprise value of the entire business, accounting for net debt, and compares it to sales volume to identify whether the asset is overvalued or undervalued. By analyzing the ratio of enterprise value to annual revenue, an investor can see the premium for the monopoly status of Soleno Therapeutics (SLNO), driven by the patent protection of orphan drugs, which makes the asset resilient to competition and justifies high multiples.